HIF-PHIs Show Short-Term Efficacy and Safety
A current meta-analysis of HIF-PHIs showed that these drugs improve the response rate of hemoglobin and decrease hepcidin levels.
All articles by Natasha Persaud
Factors Contributing to Darbepoetin Responsiveness in CKD
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.
Vadadustat Noninferior to Darbepoetin in CKD
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.
Ferric Citrate May Improve Iron Parameters Better Than Ferrous Sulfate in CKD
Transferrin saturation and ferritin concentrations improved significantly more in the ferric citrate than ferrous sulfate group over 12 weeks.
Anemia Tied With IgA Nephropathy Progression
Low hemoglobin levels in patients with IgAN increase their risk for end-stage kidney disease, according to new research.
Daprodustat Noninferior to ESA in Hemodialysis Cases
In a phase 3 trial, mean hemoglobin was maintained within target range during 52 weeks of treatment with oral daprodustat.
Anemia May Increase Risk for Kidney Failure
Investigators found sex and racial differences in the risk for end-stage kidney disease among patients with CKD anemia.
Limited ESA Use in COVID-19 Patients Recommended
Infection with the virus that causes COVID-19, coupled with use of erythropoiesis-stimulating agents may result in additive prothrombotic effects, according to the authors.
Molidustat Noninferior to Darbepoetin in Nondialysis CKD
In 2 Japanese trials of nondialysis patients, molidustat proved noninferior to darbepoetin alfa, an erythropoiesis-stimulating agent, in correcting and maintaining hemoglobin levels over 36 weeks.
ADT Use for Prostate Cancer Increases Anemia Risk
Treatment with androgen deprivation therapy alone is associated with increased risks for anemia compared with radical prostatectomy alone, a study found.
-
Loading...
-
Loading...
